Celcuity, Inc. (NASDAQ:CELC – Free Report) – Equities research analysts at HC Wainwright decreased their Q3 2026 earnings per share estimates for Celcuity in a note issued to investors on Wednesday, July 15th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($1.22) for the quarter, down from their previous estimate of ($1.17). HC Wainwright has a “Buy” rating and a $155.00 price target on the stock. The consensus estimate for Celcuity’s current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Celcuity’s Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($4.12) EPS, Q1 2027 earnings at ($0.63) EPS, Q2 2027 earnings at ($0.41) EPS, Q3 2027 earnings at ($0.23) EPS and FY2027 earnings at ($0.95) EPS.
Several other research firms have also recently weighed in on CELC. Weiss Ratings raised Celcuity from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, June 4th. Guggenheim reaffirmed a “buy” rating on shares of Celcuity in a report on Wednesday, June 3rd. Macquarie Infrastructure set a $160.00 price target on Celcuity in a report on Thursday, May 28th. Needham & Company LLC reaffirmed a “buy” rating and issued a $157.00 price objective on shares of Celcuity in a report on Friday, May 15th. Finally, Wall Street Zen cut Celcuity from a “hold” rating to a “sell” rating in a research report on Saturday, April 25th. Eleven analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $155.18.
Celcuity Stock Performance
Shares of CELC stock opened at $88.29 on Friday. The company has a market capitalization of $4.31 billion, a P/E ratio of -22.64 and a beta of 0.16. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31. The stock has a 50 day moving average price of $109.02 and a two-hundred day moving average price of $110.95. Celcuity has a fifty-two week low of $13.47 and a fifty-two week high of $151.02.
Celcuity (NASDAQ:CELC – Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10.
Insider Transactions at Celcuity
In other Celcuity news, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the transaction, the director directly owned 6,760 shares in the company, valued at $949,509.60. This represents a 57.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction on Monday, May 4th. The stock was sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the transaction, the director owned 65,000 shares of the company’s stock, valued at approximately $9,144,200. This represents a 27.78% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 13.33% of the company’s stock.
Institutional Investors Weigh In On Celcuity
Large investors have recently added to or reduced their stakes in the stock. EverSource Wealth Advisors LLC lifted its position in Celcuity by 1,329.2% in the fourth quarter. EverSource Wealth Advisors LLC now owns 343 shares of the company’s stock worth $34,000 after buying an additional 319 shares during the last quarter. US Bancorp DE raised its stake in shares of Celcuity by 25.4% in the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after acquiring an additional 143 shares during the period. BNP Paribas Financial Markets lifted its holdings in shares of Celcuity by 78.9% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after acquiring an additional 1,167 shares during the last quarter. Parallel Advisors LLC purchased a new position in shares of Celcuity during the 1st quarter worth about $38,000. Finally, Meeder Asset Management Inc. purchased a new position in shares of Celcuity during the 4th quarter worth about $42,000. 63.33% of the stock is owned by institutional investors.
Celcuity News Summary
Here are the key news stories impacting Celcuity this week:
- Positive Sentiment: Citizens JMP raised its price target on Celcuity to $177 from $160 and kept an “outperform” view, signaling confidence in the company’s upside after the approval. Citizens Jmp Issues Positive Forecast for Celcuity (NASDAQ:CELC) Stock Price
- Positive Sentiment: The FDA approved REVTORPYK for advanced HR+/HER2- breast cancer, a major regulatory milestone that could open the door to Celcuity’s first commercial product and future revenue. Celcuity Gets FDA Approval for Breast Cancer Drug
- Positive Sentiment: Multiple reports highlighted the approval as a potentially transformative event for Celcuity, with some analysts suggesting the drug’s success could make the company an attractive acquisition target for larger pharmaceutical firms. With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
- Neutral Sentiment: Celcuity held a discussion and transcript on its FDA approval and commercial launch plans, which may provide more detail on timing and launch execution but does not by itself change the fundamental story. Celcuity Inc. (CELC) Discusses FDA Approval of REVTORPYK for Advanced HR+/HER2- Breast Cancer and Commercial Launch Plans Transcript
- Negative Sentiment: Investors were also focused on rollout risks, including a delayed launch timeline and tolerability concerns, which appear to be outweighing the approval news in the near term. Celcuity shares fall as delayed breast cancer drug launch eclipses first US FDA approval
- Negative Sentiment: Several reports noted that despite the FDA win, concerns about commercialization timing and competitive pressure are weighing on the stock. Celcuity Shares Down, FDA Approval Outweighed by Timeline Questions for Breast-Cancer Treatment
About Celcuity
Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.
Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.
Featured Stories
- Five stocks we like better than Celcuity
- Has Broadcom Become Too Expensive for Its AI Story?
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
Receive News & Ratings for Celcuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celcuity and related companies with MarketBeat.com's FREE daily email newsletter.
